Policies and Instructions on Abstract Submission
Extremity War Injuries XVII

Submission Deadline Extended: September 1, 2023

Policies Governing Accepted Submissions:

1. Abstracts must be submitted online by September 1, 2023 to be eligible for review by the Program Committee.
2. Once an abstract is accepted, additional authors cannot be added.
3. Acceptance or rejection letters and all future correspondence will be emailed to the Primary Contact listed on the Abstract Submission Form. Notification of acceptance will be sent by October 2023 to the email address provided on the submission form. Failure to return Presenter Forms attached to the acceptance email, by the date listed, may result in the presentation being removed from the program.
4. Abstracts not accepted for a podium presentation may be accepted for a Poster presentation.
5. The paper is to be original, unpublished work focused on trauma or readiness or both.
6. All co-authors must complete a disclosure form, or your presentation will be eliminated from the meeting.
7. SOMOS reserves the right to publish the accepted abstracts in a medical journal. This will not preclude publishing the manuscript in another journal.
8. SOMOS reserves the right to withdraw a presentation at any time.

Instructions to complete abstract submission:

1. TITLE: Make the title brief and clearly indicate the nature of the study/procedure. Do not use all caps. Please do not use similar titles for numerous submissions.
2. CONTENT: The abstract must include four parts: INTRODUCTION should clearly state the problem and the purpose of the study; METHODS should provide a description of what was actually done; RESULTS should contain the findings of the study; DISCUSSION/CONCLUSION should be based upon the findings and relate to the stated purpose of the study and existing knowledge. Provide specific details about your research/study. A two-year minimum follow-up per patient is required for all results for reconstructive procedures and new or modified techniques as they relate to diagnosis, surgery, complications or other phases of orthopaedic surgical problems.
3. LENGTH: The abstract should be typed on the form provided within space allotted. Additional pages will not be accepted. Use English only.
4. STYLE: Use title case for the entire title. DO NOT include company names, titles, appointments or addresses in the abstract. DO NOT use subtitles. Standard abbreviations may be used, when necessary. Do not cite references. Omit P values. No reference is to be made in your text as to authors, institutions, clinics, pharmaceutical companies, or specific manufacturers. Please check your work prior to submission. The Society of Military Orthopaedic Surgeons is not responsible for proofreading or accuracy.
5. DRUG NAMES: Nonproprietary (generic) names of drugs are required and should be written in lower case. Proprietary names are capitalized.
6. SUBMISSIONS: An Electronic Submission form is provided below for all submissions. The abstract submission deadline for EWI XVII Meeting is September 1, 2023.
7. NOTIFICATION OF ACCEPTANCE: The Program Committee will review Abstracts. You will be notified of acceptance by email by October 2023. The Society of Military Orthopaedic Surgeons reserves the right to withdraw a paper at any time.
8. REGISTRATION FEES: All presenters are required to register for the meeting and pay the registration fee.

Podium Presentation

Each Podium presentation will be approximately 4-8 minutes in length. Standard audiovisual equipment in the scientific session room includes an LCD projector and Windows Computer (not a Mac). Personal laptops will not be used for presentations.

Poster Presentation

Poster presentations will be shown for the entire meeting (2 days).

Grading Process

• Abstracts will be read in a “blind” fashion. Your text should not reveal the authors or institutions of origin.
• Graders are orthopaedic surgeons and are members of the Program Committee. Each abstract is reviewed and graded by at least four individuals/orthopaedic surgeons and the final grade is then averaged.
• Grade is influenced by: significance of the study, content and clarity, specific number of cases or specimen studies, clinical or research data to support its conclusions, minimum follow-up of 2 years per patient for results describing reconstructive procedures, and new or modified techniques as they relate to diagnosis, surgery, complications or other phases of orthopaedic surgical problems.

Submission Agreement

• All authors must agree to the following statements on the submission form for this abstract to be considered.
• We, the listed authors on this abstract, submit this abstract for presentation consideration to SOMOS. We affirm that the information contained in this abstract fairly and accurately represents original work.
• We agree that, if accepted for inclusion in a SOMOS meeting, the published abstract and presentation will represent the same data as originally submitted herein.
• We assume full responsibility for securing the necessary clearance and permission for publication and presentation from any contracting supervisory research agency holding presentation material copyrights. SOMOS requires that Podium Presenters, Co-Authors and all Poster Presenters provide their financial disclosure online.
• We agree that any and all financial interest in the product or process involved with our research will be properly identified. This includes stock ownership, membership on an advisory board or board of directors, corporate sponsored research, or any other substantive relationship. Please note that financial disclosure does not disqualify an abstract from consideration or presentation.
• We agree that disclosure will be made if a presentation includes substances or products not approved in the U.S. for the use under discussion.
• We understand and grant release to SOMOS to make any recordings of our presentation. We authorize the recording of our presentation for any related purposes.

Submit your abstract today!